Teva Pharma (TEVA) Misses Q3 EPS by 3c; Lowers Revenue Outlook on FX

Teva Pharma (NYSE: TEVA) reported Q3 EPS of $0.59, $0.03 worse than the analyst estimate of $0.62. Revenue for the quarter came in at $3.6 billion versus the consensus estimate of $3.85 billion.

GUIDANCE:

Teva Pharma sees FY2022 EPS of $2.40-$2.60, versus the consensus of $2.50. Teva Pharma sees FY2022 revenue of $14.8-15.4 billion, versus prior guidance of $15-15.6 billion and the consensus of $15.46 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• Syra Health names Dr. Cori McMahon as fractional chief medical officer
• DA Davidson Reiterates Neutral Rating on WW Grainger (GWW), Notes Tactical Upside Potential